These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

987 related articles for article (PubMed ID: 22770960)

  • 1. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
    Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
    Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck.
    Pinette A; McMichael E; Courtney NB; Duggan M; Benner BN; Choueiry F; Yu L; Abood D; Mace TA; Carson WE
    Cancer Immunol Immunother; 2019 Aug; 68(8):1379-1389. PubMed ID: 31338557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.
    Roda JM; Joshi T; Butchar JP; McAlees JW; Lehman A; Tridandapani S; Carson WE
    Clin Cancer Res; 2007 Nov; 13(21):6419-28. PubMed ID: 17962339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells.
    López-Albaitero A; Lee SC; Morgan S; Grandis JR; Gooding WE; Ferrone S; Ferris RL
    Cancer Immunol Immunother; 2009 Nov; 58(11):1853-64. PubMed ID: 19319529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.
    Stephenson RM; Lim CM; Matthews M; Dietsch G; Hershberg R; Ferris RL
    Cancer Immunol Immunother; 2013 Aug; 62(8):1347-57. PubMed ID: 23685782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck.
    Taylor RJ; Chan SL; Wood A; Voskens CJ; Wolf JS; Lin W; Chapoval A; Schulze DH; Tian G; Strome SE
    Cancer Immunol Immunother; 2009 Jul; 58(7):997-1006. PubMed ID: 18979096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.
    Srivastava RM; Lee SC; Andrade Filho PA; Lord CA; Jie HB; Davidson HC; López-Albaitero A; Gibson SP; Gooding WE; Ferrone S; Ferris RL
    Clin Cancer Res; 2013 Apr; 19(7):1858-72. PubMed ID: 23444227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effects of interferon-gamma on squamous-cell carcinoma of head and neck targets in antibody-dependent cellular cytotoxicity mediated by human natural killer cells.
    Sung MW; Johnson JT; Van Dongen G; Whiteside TL
    Int J Cancer; 1996 May; 66(3):393-9. PubMed ID: 8621263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-21 enhances NK cell activation in response to antibody-coated targets.
    Roda JM; Parihar R; Lehman A; Mani A; Tridandapani S; Carson WE
    J Immunol; 2006 Jul; 177(1):120-9. PubMed ID: 16785506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab.
    Taylor RJ; Saloura V; Jain A; Goloubeva O; Wong S; Kronsberg S; Nagilla M; Silpino L; de Souza J; Seiwert T; Vokes E; Villaflor V; Cohen EE
    Cancer Immunol Res; 2015 May; 3(5):567-74. PubMed ID: 25769300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck.
    Bier H; Hoffmann T; Haas I; van Lierop A
    Cancer Immunol Immunother; 1998 May; 46(3):167-73. PubMed ID: 9625540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural killer (NK) cells as effectors of antibody-dependent cytotoxicity with chimeric antibodies reactive with human squamous-cell carcinomas of the head and neck.
    Sung MW; Yasumura S; Johnson JT; Van Dongen GA; Whiteside TL
    Int J Cancer; 1995 Jun; 61(6):864-72. PubMed ID: 7790123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.
    Roberti MP; Barrio MM; Bravo AI; Rocca YS; Arriaga JM; Bianchini M; Mordoh J; Levy EM
    Breast Cancer Res Treat; 2011 Nov; 130(2):465-75. PubMed ID: 21308409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status.
    Baysal H; De Pauw I; Zaryouh H; De Waele J; Peeters M; Pauwels P; Vermorken JB; Smits E; Lardon F; Jacobs J; Wouters A
    Br J Cancer; 2020 Sep; 123(5):752-761. PubMed ID: 32541873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
    Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
    Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients.
    Trivedi S; Srivastava RM; Concha-Benavente F; Ferrone S; Garcia-Bates TM; Li J; Ferris RL
    Clin Cancer Res; 2016 Nov; 22(21):5229-5237. PubMed ID: 27217441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid.
    Kumai T; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Kobayashi H
    Head Neck; 2016 Mar; 38(3):410-6. PubMed ID: 25352398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.
    Wu L; Parton A; Lu L; Adams M; Schafer P; Bartlett JB
    Cancer Immunol Immunother; 2011 Jan; 60(1):61-73. PubMed ID: 20848094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
    Roda JM; Parihar R; Carson WE
    J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.
    Carson WE; Parihar R; Lindemann MJ; Personeni N; Dierksheide J; Meropol NJ; Baselga J; Caligiuri MA
    Eur J Immunol; 2001 Oct; 31(10):3016-25. PubMed ID: 11592078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.